Introduction
Iodine is an essential trace element for human health. Iodine functions as a component of thyroid hormones, thyroxine (T4) and triiodothyronine (T3) (Health Canada, 2012) . Thyroid hormones are involved in regulating the body's metabolic processes and play a role in normal growth and development, particularly, in healthy brain development (CDC, 2012; WHO, 2007) . According to the WHO, iodine deficiency is the single most important preventable cause of brain damage (WHO, 2007) . Given the importance of adequate iodine intake for thyroid hormone synthesis and normal neurodevelopment, pregnant and lactating women and their offspring are the groups most vulnerable to iodine deficiency. Even a mild thyroid hormone insufficiency in pregnancy can produce measurable effects in very specific neurological functions (Ghirri et al., 2014; Zoeller and Rovet, 2004) . The developmental timing of the thyroid hormone deficiency is critical to the type of neurological deficits that occur in the developing brain (Zoeller and Rovet, 2004) . In humans, the thyroid hormone deficiency in the first and the second trimesters can have adverse effects in visual attention, visual processing, visuospatial skills and fine motor skills. If the deficiency occurs in late pregnancy, gross motor skills and memory can be affected (Zoeller and Rovet, 2004) . Iodine deficiency in newborns can have predominant effects on verbal skills, language and motor function (Zoeller and Rovet, 2004) . Iodine deficiency in newborns can also cause goiters and moderate to severe hypothyroidism (Ghirri et al., 2014; Katz et al., 2013) .
Adverse effects associated with excess iodine intake are less obvious; the major epidemiological consequence of iodine excess is iodine-induced hyperthyroidism (WHO, 2007; Health Canada, 2012) . Excess iodine intake has also been associated with thyroiditis, goiter, hypothyroidism, sensitivity reactions, thyroid papillary cancer, and acute toxic responses in some individuals (IOM, 2001) .
Iodine is present in food and water primarily as iodide. Dietary sources of iodine include foods where iodine is added as a supplement (e.g., iodized salt, breads) as well as dairy products, and seafood (Health Canada, 2012) . In North America, and much of the world, the addition of iodine to salt for table or household use is mandatory to prevent iodine deficiency (Health Canada, 2012) . In households where food is prepared at home, iodized salt is the predominant source of iodine intake (Zimmermann and Andersson, 2012) . However, most salt intake in Western diets (approximately 70%) is derived from processed food which is principally non-iodized salt (Caldwell et al., 2011) . Murray et al. (2008) found that the primary contributors to dietary intake of iodine in the US population are dairy products and grains.
Due to the adverse outcomes associated with both iodine deficiency and excess iodine intake, assessing population iodine status is an imperative public health initiative. The use of median urinary iodine concentrations (UIC) from a population study is the most common measure used for examining iodine status in populations (WHO, 2007) . The UIC is a well-accepted, cost-efficient and easily obtainable indicator for iodine status (WHO, 2007; . UIC spot samples have been measured in large biomonitoring studies in North America including the National Health and Nutrition Examination Survey (NHANES) in the United States (US) and the Canadian Health Measures Survey (CHMS). Population iodine status is commonly evaluated by comparing the population median urinary iodine spot samples to threshold values derived by the World Health Organization (WHO) (WHO, 2007; Caldwell et al., 2011; Statistics Canada, 2013; Juan et al., 2016) . The IOM and the US Agency for Toxic Substances and Disease Registry (ATSDR) have established exposure guidance values for iodine deficiency and excess intake for North Americans. These values are presented either as daily iodine intake (i.e., μg/d) or as a urinary creatinine adjusted value (i.e., μg/g creatinine) rather than UIC in μg/L, which is the biomarker recommended by the WHO for assessing iodine status (IOM, 2001; ATSDR, 2004; WHO, 2007) . The purpose of this paper is to derive urine equivalent concentrations for the iodine exposure guidance values based on oral intake rates (ug/d) for North America using the Biomonitoring Equivalent approach.
The concept of Biomonitoring Equivalents (BEs) has been developed (Hays et al., 2007) , and guidelines for the derivation and communication of these values have been prepared LaKind et al., 2008) . A Biomonitoring Equivalent (BE) is defined as the concentration or range of concentrations of a chemical or its metabolites in a biological medium (blood, urine, or other medium) that is consistent with an existing health-based exposure guidance value such as a reference dose (RfD) or Tolerable Daily Intake (TDI). Thus, the BE carries the same functional definition and intended use as the underlying guidance value (e.g., use for evaluating population risks the same as the RFD and TDI are intended). Existing chemical-specific pharmacokinetic data are used to estimate biomarker concentrations that are consistent with the Point of Departure (POD) used in the derivation of an exposure guidance value (such as the RfD or TDI), and with the exposure guidance value itself. BEs can be estimated for other types of exposure guidance values, including recommended intakes of nutritionally essential elements (e.g., selenium, Hays et al., 2014) . BEs can be estimated using available human or animal pharmacokinetic data , and BEs have been derived for over 100 compounds to date (Aylward et al., 2013) .
BE values are one of the tools available for the assessment of biomonitoring data (Angerer et al., 2011) . These are intended to be used as screening tools to inform priority setting for risk assessment or risk management of exposures to chemical substances, in the same way that an RfD or TDI is used to evaluate estimated intakes of a chemical. For multiple chemicals, BE values have been used to evaluate CHMS and NHANES biomonitoring data across chemicals to examine relative levels of exposure in the context of risk assessment-derived exposure guidance values (St-Amand et al., 2014; Aylward et al., 2013) . The derived BE values are only as robust as the underlying exposure guidance values and pharmacokinetic data used to derive them. BE values can leverage work conducted in existing risk assessments and place population-level biomonitoring data in a health risk context. While BE values are not intended to be used for assessing biomonitoring data from individuals or for diagnostic purposes, they are consistent with the usual application of the underlying risk assessment-derived exposure guidance values .
Methods

Exposure guidance values
The IOM (2001) has derived Estimated Average Requirement (EAR) and Recommended Dietary Allowances (RDAs) to ensure nutritional adequacy of iodine intake. The EAR is the average daily nutrient intake level that is estimated to meet the requirement of half of the healthy individuals in a life-stage and sex group (IOM, 2001; Health Canada, 2010) . The EAR is used to understand the average nutritional needs of a population. The RDA is derived from the EAR (by adding two standard deviations) and represents the average daily dietary intake level that is sufficient to meet the nutritional requirements of nearly all (97-98 percent) of the healthy individuals in the demographic group (IOM, 2001; Health Canada, 2010) . The RDA is the target nutritional intake level for an individual (Health Canada, 2010) . Similar to the RDA, the WHO has established a Recommended Nutrient Intake (RNI) for iodine to meet the nutrient requirements of almost all (97.5%) of healthy individuals in an age and sex-specific group (Table 1) (WHO, 2004) . These values were established by estimating the average intake rates required to ensure nutritional sufficiency for normal thyroid function. The EAR, RDA and RNI values are delineated by age group and pregnancy status and are presented in Table 1 .
Exposure guidance values have also been established to protect against adverse effects of excess iodine exposure. The IOM identified increased thyroid stimulating hormone (TSH), which can result in increased risk of clinical hypothyroidism, as the critical adverse effect for evaluation of the Tolerable Upper Intake Level (UL) (IOM, 2001) . In two studies of controlled iodine administration in adults over a period of two weeks, intakes of approximately 1700-1800 μg/d resulted in increased levels of TSH (Paul et al. (1988) and Gardner et al., 1988 , as reported in IOM, 2001 ). The IOM evaluation identified the lowest of these as the lowest observed adverse effect level (LOAEL). The evaluation concluded that uncertainty about extrapolation to a tolerable exposure level was low (due to the mild and reversible nature of the elevated TSH effects selected for the POD), and that an uncertainty factor of 1.5 was appropriate. This resulted in a UL of 1100 μg/d.
Both the ATSDR and the International Programme on Chemical Safety (IPCS) set exposure guidance values for iodine based on increases in thyroid stimulating hormone levels and increased prevalence of goiter in a high-exposure group of children compared to a lower-exposed group (Boyages et al., 1989; as cited in IPCS, 2009 ). The Minimal Risk Level (MRL) from ATSDR and the Tolerable Daily Intake (TDI) from the International Programme on Chemical Safety (IPCS) were derived based on the identification of a LOAEL of 1236 μg/g creatinine and a NOAEL of 428 μg/g creatinine iodine in urine in the lower exposure group (Table 2) . Urine samples were collected from the participants involved in the study and iodine was quantified and reported as μg I/g creatinine. Based on the urinary excretion rates and average 
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Regulatory Toxicology and Pharmacology 94 (2018) 40-46 body weights, LOAEL and NOAEL iodine intake rates were identified and reported in terms of mg/kg-d. The NOAEL was selected as a point of departure (POD), and no additional uncertainty factors were deemed to be required to protect against adverse effects (Table 2) .
Pharmacokinetic data
Population median UIC has been identified as the population biomarker for recent iodine intake because ≥92% of dietary iodine is absorbed through the GI tract in healthy adults and excreted in the urine within 24-48 h (Cockell, 2015; Zimmermann and Andersson, 2012; Caldwell et al., 2011) . The population median UIC can be used a biomarker for both iodine deficiency and excess exposure. Since biomonitoring for iodine exposures involves quantifying UICs, the only pharmacokinetic (PK) information required for deriving a BE is the urinary excretion fraction (Fue), correlations between iodine intake and urinary excretion rates of iodine, or measures of urinary iodine concentrations in the studies underlying the exposure guidance values. Several studies have been conducted to measure both the Fue and correlations between dietary intake and urinary excretion of iodine.
• Nath et al. (1992) increased the daily intake of iodine-fortified sodium chloride (NaCl) by 1, 3, 6, and 9 mg/24 h, each for a two day period amongst twelve healthy adult volunteers. This resulted in increased iodine daily doses of 10, 40, 70 and 110 μg/day over background intake in these subjects. The authors reported that 92% of the additional iodine dose was excreted in urine (Nath et al., 1992) with a linear regression fit of UI (μg/day) = 110 + 0.92 * IDD (μg/day), where UI is urinary iodine excretion and IDD is iodine daily dose.
• Vought and London (1964) monitored iodine intake (via analysis of matched diet samples) and urinary and fecal excretion of iodine amongst 19 subjects living in five households for five consecutive days for one week and followed by one day a week for an additional five weeks. Using the mean daily intake and urinary excretion, the authors report that 97% of iodine intake was eliminated in urine, with a regression equation of UI (μg/day) = 22 + 0.97 * IDD (μg/ day) (Vought and London, 1964 ).
• In a follow-up to their 1964 study, Vought and London (1967) provided three controlled daily doses of iodine (ranging from 27.7 to 606.5 μg I/day) for 54 days (18 days at each intake level) to three in-patient volunteers. The results of the experiment verified the hypothesis that iodine excretion has a linear correlation with iodine intake. The results also demonstrated that there was an obligatory excretion of iodine independent of the intake levels, which amounted to 57 μg I/day, likely from endogenous sources. Each of the studies found a positive intercept, suggesting either total iodine intake was not adequately accounted for or endogenous (stored) sources of iodine predominates iodine in urine at low iodine intake levels. The latter possibility could suggest a constant turnover/metabolism of iodine even in the absence of iodine intake (unless physiological iodine stores are depleted). The possibility of a non-linear relationship between iodine intake and urinary excretion has not been reported in any of the available studies. For the purposes of the derivations of exposure guidance values, the apparent intercepts in these datasets were ignored by the various agencies. Thus, the exposure guidance values in Table 2 were based on toxicology studies that measured either 24-h urinary excretion of iodine (μg/24-hr) or UIC in spot urine samples (μg/g creatinine) as the dose metric for assessing exposure-response. The exposure guidance values (in μg/d) were then derived from the 24 h urinary iodine excretion rate (μg/d) with the assumption of 90% of iodine intake is excreted in urine (IOM, 2001; ATSDR, 2004; IPCS, 2005) .
BE derivation approach
The BEs associated with the exposure guidance values are derived here using the convention of deriving BEs, which rely on human epidemiology studies using two general approaches:
• For the nutritional guidance values (EAR, RDA and RNI), BEs are derived using the urinary mass balance approach and using an Fue of 0.9 (IOM, 2001) . Specifically, the BE value associated with the EAR and RDA can be calculated based on the urinary excretion fraction (Fue) and age-specific assumptions regarding the daily urinary volume (V 24 ) or creatinine excretion rate (Cr 24 ).
(1)
The nutritional guidance values were set based on adults and then extrapolated to different age groups based on bodyweight scaling that was not clearly described. Thus, the BE values presented here were derived first for adult EAR, RDA and RNI values. Because children have generally higher urinary flow per kg bodyweight and lower creatinine excretion rate per kg bodyweight, the urinary concentrations corresponding to the same daily intake rates on the basis of bodyweight scaling (i.e., μg/kg-d) will differ from those in adults. BEs for the age group 6-10 years old were derived by using age appropriate urinary flow and creatinine excretion rates per kg bodyweight. BEs were not generated for guidance values targeted toward populations undergoing unique physiological changes such as pregnant women as daily urine volumes and creatinine excretion rates will vary greatly in these populations.
• For the exposure guidance values designed to protect against toxicity resulting from elevated iodine exposures (MRL, TDI, UL), the underlying studies either reported 24-hr urinary iodine excretion (Table 2) at the NOAEL or LOAEL associated with the adverse response of interest. These PODs were converted to intake rates by the agencies involved by assuming an Fue of 0.9. The selected intake rates in mg/kg-d corresponding to the UL, MRL, and TDI were used to estimate BE values for adults and children aged 6-10 years old. This was carried out using the standard assumptions for urinary flow and creatinine excretion rate per kg bodyweight for adults (20 ml/kg-day, 20 mg creatinine/kg-day) and children aged 6-10 years old (25 ml/kg-day, 19 mg creatinine/ kg-day) (Aylward et al., 2015) . Table 3 provides the BE values derived from EAR, RDA and RNI. The BE value consistent with the EAR is 60 μg/L (60 μg/g creatinine) for adults and 50 μg/L (60 μg/g creatinine) for children ages 6 to 10. The BE value consistent with the RDA and RNI (150 μg/day) is 100 μg/L (100 μg/g creatinine) for adults and 80 μg/L (100 μg/g creatinine) for children ages 6 to 10. When rounded, BE values for children ages 6 to 10 are similar or slightly lower than adult values on a urinary concentration basis, reflecting higher urinary flow rates per kg bodyweight, and similar to slightly higher on creatinine-corrected basis, reflecting slightly lower creatinine excretion rates per kg bodyweight in this age group compared to adults.
Results
The NOAELs from the critical studies (Boyages et al., 1989; Li et al., 1987) used for estimating ATSDR MRL and IPCS TDI were used as the basis for derivation of the BE value corresponding to the MRL and TDI (Table 3) . When deriving UL, IOM used an UF of 1.5 to account for using LOAEL instead of NOAEL. For adults, the BE value associated with the ATSDR MRL and IPCS TDI is 450 μg/L (450 μg/g creatinine), and the BE associated with the IOM UL is 730 μg/L (730 μg/g creatinine). For children, the BE corresponding to the ATSDR MRL and IPCS TDI is 360 μg/L (470 μg/g creatinine), and the BE associated with the IOM UL is 580 μg/L (770 μg/g creatinine).
Discussion
The BE values presented in this manuscript describe a target range for UICs that allow for the evaluation of urinary iodine in population studies in terms of both nutritional sufficiency and of avoidance of elevated exposures sufficient to result in adverse effects. The BE values represent estimates of the average urinary concentrations associated with the various nutritional and toxicity exposure guidance values. The pharmacokinetics of iodine have been well studied in humans, and the exposure-response relationships for iodine deficiency, adequacy and excess are well understood.
The BE values presented here can be compared to epidemiologically-derived recommendations for assessing population iodine exposures by the World Health Organization (WHO, 2007) (Table 4) . The WHO conducted an epidemiology study to assess the direct relationship between UIC and adverse effects from too low of and too high of iodine intakes. According to the WHO (2007) cut-points, median population UICs below 100 μg/L indicate a degree of iodine insufficiency in the population group. This is consistent with the calculated BE values for the RDA and RNI presented in Table 3 . The derived BE for EAR (i.e. 60 μg/L) is below the WHO cut-point for nutrition adequacy. Further, the WHO categories indicate an increasing risk of adverse effects of elevated exposures when population median UICs exceed 300 μg/L, while the BE values, derived based on the MRL and TDI, are somewhat higher than this level. Notably, the BE values based on the IOM UL are significantly higher than the WHO category cut-point. This is consistent with the difference in the underlying assessments, with IOM establishing a higher UL value compared with the TDI and MRL values (Table 2) . Overall, the derived BE values align well with the WHO categories, particularly given the individual variability and uncertainty associated with urinary flow and creatinine excretion rates.
The BE values for EAR, RDA and UL derived in the current study are Table 3 Derivation of urinary BE values for Iodine based recommendations for adequate intake to meet nutritional requirements (see Table 1 ) and exposure guidance values designed to protect against toxicity resulting from elevated exposures (see Table 2 ). Alterations in TSH and increased goiter incidence (Boyages et al., 1989) Alterations in TSH and increased goiter incidence (Boyages et al., 1989) Increased TSH levels (Paul et al., 1988) 60 (60) 100 (100) 450 (450) 450 (450) 730 (730) Children ages 6-10, μg/L (μg/g creatinine) d :
50 (60) 80 (100) 360 (470) 360 (470) 580 (760) a The LOAEL from Paul et al., (1988) was expressed in units of daily iodine intake, 1.7 mg/d, and divided by a standard 70 kg BW. b The RDA and RNI for adults were divided by a standard bodyweight of 70 kg. c BE values were calculated using equation (1), an Fue of 0.9, and a daily urinary volume of 20 ml/kg-d or daily urinary creatinine excretion rate of 20 mg/kg-d (Aylward et al., 2015) . d BE values for children ages 6-10 were calculated using equation (1), an Fue of 0.9, and a daily urinary volume of 25 ml/kg-d or daily urinary creatinine excretion rate of 19 mg/kg-d (Aylward et al., 2015) . Likely to provide adequate intake for pregnant/lactating women but may pose a slight risk of more than adequate intake. ≥300 Excessive Risk for adverse health consequences (e.g., iodine-induced hyperthyroidism, autoimmune thyroid diseases) a Applies to adults, but not to pregnant and lactating women.
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Regulatory Toxicology and Pharmacology 94 (2018) 40-46 in line with the UICs derived by other investigators for the same exposure guidance values. Zimmermann and Andersson (2012) The BE values derived in the present study are only as robust as the underlying exposure guidance values. All the assumptions and uncertainties used in estimating exposure guidance values are applicable to derived BEs. BE values represent central tendency estimates of the long-term steady-state concentrations of iodine in urine associated with steady-state exposure at the various exposure guidance value benchmarks. Because there is within-and between-individual and temporal variations in both intake rates and factors such as the rates of urinary flow and creatinine excretion in the general population (Rohner et al., 2014; Zimmermann and Andersson, 2012; Aylward et al., 2014) , these BE values are most appropriately used in the evaluation of the central tendency of UICs on a population basis (with the population being defined consistent with the intent of the underlying risk value). Note that the BE for the RDA is more representative of a value that is sufficient to meet the needs of nearly all of the healthy individuals in a population for a particular life-stage and gender group rather than the central tendency. The RDA is the goal for usual intake of iodine by an individual. Caution should be taken when using this value to interpret population level iodine status.
It is important to note that neither spot UIC nor 24-h measurements are adequate biomarkers for estimating prevalence of inadequate and excess iodine intakes of individuals (Zimmermann and Andersson, 2012; Rohner et al., 2014) . Daily individual variation in dietary iodine intakes results in highly variable day-to-day UICs. It is difficult to measure individual dietary intake of iodine due to variation in eating habits, difficulty in estimating iodine levels from salt intake, lack of information on type of salt used in processed food, and the amount of iodine content in natural food (Rohner et al., 2014; Zimmermann and Andersson, 2012) . UIC data (both spot and 24-h urine samples) from iodine-sufficient countries, where most iodine intake comes from iodized salt, have shown 30-40% within-individual day-to-day variation in iodine levels (Zimmermann and Andersson, 2012) . As a result, an individual with sufficient iodine intake for normal thyroid function may have many individual days where their UIC value could be less than what would be deemed adequate (Zimmermann and Andersson, 2012) . UICs also depend on the temporal variation in iodine intake levels on the day of the survey. Accordingly, the number of individuals who are deficient or have excess iodine levels based on WHO reference ranges is often misinterpreted (Rohner et al., 2014; Zimmermann and Andersson, 2012) . Several investigators have emphasized the importance of collecting repeated urine samples to increase the accuracy of predictions of individual iodine status (Rohner et al., 2014; Zimmermann and Andersson, 2012; Konig et al., 2011; Andersen et al., 2001) . Data presented in Konig et al. (2011) showed that even with 10-repeated urine samples per participant, only about 20% precision was obtained for both crude UIC and 24-h urine iodine excretion.
There is also considerable discussion among the scientific community regarding the reliability of using creatinine corrected values when expressing iodine status. Populations with protein malnutrition are expected to have lower creatinine excretion rate resulting in inaccurate UICs when adjusted for creatinine (Zimmermann and Andersson, 2012; Perrine et al., 2014) . Flow rates and urinary creatinine excretion rates can vary by factors of 2-3 from the central tendency for an individual across different spot samples in a day or over several days in an individual . The WHO has recommended using median urine iodine concentration (in μg/L) from spot samples to describe the iodine status of a population in order to avoid the confounding effect of protein malnutrition when corrected for creatinine (WHO, 2007; Zimmermann and Andersson, 2012; Perrine et al., 2014; Rohner et al., 2014) . The current assessment presents urinary BE values on both a volume basis (μg/L) and a creatinine-adjusted basis (μg/g creatinine) as protein malnutrition may not be as relevant for creatinine concentrations in North America versus populations which may have issues with malnutrition. Fig. 1 shows the relationship between BE values (in μg/L) based on the recommended sufficiency of intake for nutritional purposes (i.e., EAR, RDA, RNI) and those based on avoidance of potential adverse effects (i.e., UL, MRL, TDI). Also illustrated are the median values from US adults and children ages 6 to 11 from the NHANES (2003) (2004) (2005) (2006) (CDC, 2012) and the CHMS (2009) (2010) (2011) (Statistics Canada, 2013) . The population median UIC values for children from NHANES and CHMS (232, 189 μg/L, respectively) fall well into the "sufficient" iodine region, above the BE values associated with nutritional adequacy and below those associated with excessive exposure. The population median UICs for NHANES and CHMS adults (140-181, 122-126 μg/L, respectively) are just above the BE corresponding to the IOM EAR and RDA and WHO RNI. In addition, population median UICs in Canada and the US do not exceed the BEs associated with the TDI, MRL, UL or the WHO cut-point for excessive intake. This interpretation is in line with the WHO epidemiological criteria for assessing iodine nutrition (Table 4) , where the median UICs from NHANES children are considered to be above requirements (but not excessive) and the UICs from CHMS children, NHANES adults and CHMS adults are adequate. Based on this analysis, the populations of US and Canada are likely to have adequate population iodine nutrition. Pan et al. (2013) conducted an analysis of NHANES data for specific demographic categories (i.e. sex, race/ethnicity, women of childbearing age and pregnant women). According to this analysis, the population-weighted median UIC in the US population and in all the demographic categories, except pregnant women are within the WHO (2007) cut-point for iodine adequacy (i.e. within 100-199 μg/L, Table 4 ). However, the median UIC of US pregnant women of 15-44 years of age are 145 (116.0-182.0) μg/L, which falls into WHO cut-point for iodine insufficiency for pregnant women (150 μg/L, Table 5 ).
The analyses presented here demonstrate the application of the BE S.M. Hays et al. Regulatory Toxicology and Pharmacology 94 (2018) 40-46 approach to the evaluation of UICs from a risk assessment perspective. Because iodine has been studied extensively in a public health context, the recommendations for evaluation of intake and UICs for nutritional sufficiency from various organizations, and the corresponding BE values, are very consistent. There is somewhat less agreement among different groups regarding the point at which elevated exposure may begin to lead to clinically relevant adverse effects, and the differences in this judgment are reflected in the differences in the BE values corresponding to the IOM UL compared to the WHO IPCS TDI and the ATSDR MRL. Based on the current analysis, the population median UIC from NHANES and CHMS for both children and adults are above WHO cutpoint for nutrition deficiency and the IOM EAR and below the WHO cut-point for excessive iodine intake and IOM UL. The BEs derived here can serve as a guide to help public health officials and regulators interpret population level biomonitoring data measuring UICs in a health risk context, for both nutritional adequacy of iodine based on the EAR, RDA and RNI and exceedances of BEs associated with the UL, TDI and MRL. For lactating women and children < 2 years of age a median urinary iodine concentration of 100 μg/L can be used to define adequate iodine intake, but no other categories of iodine intake are defined. Although lactating women have the same requirement as pregnant women, the median urinary iodine is lower because iodine is excreted in breast milk. b The term "excessive" means in excess of the amount required to prevent and control iodine deficiency.
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